initi coverag rx suppli chain
simpl tri make way healthcar
broadli neutral neg rx suppli chain given concern
moder drug inflat mute volum mix constant polit
uncertainti addit fundament concern esoter risk
present notabl impact valuat broadli investor fear spike
competit lt margin howev enter contend
backdrop favor share valuat rel discount tax
reform buoy ep threat crystal
dismiss threat check suggest risk overplay
respect rx suppli chain fundament see easi comp volum
front mix bottom inflat trend albeit depress level yield
improv growth addit turn threat believ
fear persist magnitud potenti threat becom local
scope full assault highli unlik view see disrupt
commodity-ori market brand name irrelev think front end
pharmaci remain highli skeptic dispens distribut thu
coupl ep upsid tax reform see consist fundament
yield valuat mean revers ultim better perform
top pick includ walgreen recommend avoid
thing watch util vertic commentari ep drop-
thru tax
debat influenti demograph util gener cliff vs
specialti boom win big threat prove
vertic integr danc continu
industri growth forecast forese rx growth us averag msd
next three year depend inflat begin firm moder
level specialti pipelin approv remain robust gener
deflat perspect see hsd ldd declin tempor modest
upward bia like balanc comp eas size
valuat price target across complex impli market cap weight price-to-earnings
ep reflect tax reform relat upsid termin growth rate
dcf primari valuat metric compar price-to-earnings rang
averag pleas note forecast current
ignor tax reform relat upsid ep dcf analysi adjust updat
cash tax rate thu view point valuat reflect tax reform pass
downsid risk potenti continu disinfl deflat pressur
hit industri profit reset oper margin lower long term threat
govern intervent broadli across complex given consum furor drug
price could harm visibl multipl entranc materi
fashion contempl could disrupt busi model compress profit
upsid risk stabil gener deflat post period disrupt
given format larg buy group could aid return posit omx improv
util due spike flu season gener uptrend given acceler econom
condit would aid profit growth push toward vertic integr provid lt
visibl industri econom given abil effect save consum system
compani initi outperform
esrx under-perform
link webinar
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi coverag rx suppli chain
im simpl tri make way
last page report import disclosur regard stock report
tabl content
industri debat influenti demograph util
industri debat gener cliff vs specialti boom win
industri debat big threat prove
industri debat vertic integr danc continu
 bull bear debat conclus
valu revers bia tax reform upsid abat risk inflat stabil better perform
broadli neutral neg rx suppli chain given concern
moder drug inflat mute volum mix constant polit uncertainti
addit fundament concern esoter risk present
notabl impact valuat broadli investor fear spike competit lt margin
enter contend backdrop favor share valuat
rel discount tax reform buoy ep threat crystal
respect rx suppli chain fundament see easi comp volum front mix
bottom inflat trend albeit depress level yield improv growth
turn threat believ fear persist magnitud potenti
threat becom local scope full assault highli unlik view
see disrupt commod orient market brand name irrelev
think front end pharmaci remain highli skeptic dispens distribut
thu coupl ep upsid tax reform see consist fundament
yield valuat mean revers ultim better perform broadli
top pick includ walgreen recommend avoid
thing watch util vertic commentari ep drop-thru tax
rel valuat point veli skew risk reward across complex
debat influenti demograph util
age babi boomer transform healthcar
nearli quarter american
demograph shift major implic
peopl age make fastest-grow group
today lead extend treatment
complex health condit challeng
healthcar system abil provid effici care
us popul
age forecast nearli doubl
healthcar spend increas age
demograph shift quickli age babi boomer
combin longer life span favor
trend healthcar industri
prescript expens increas age
age popul drive higher prescript usag
share us rx expenditur
america popul age age drug secular tailwind
debat gener cliff vs specialti boom win
end gener wave reshap channel
gdr grown percentag pt
total brand market sale expect gener launch billion
specialti drive nearli industri growth
specialti account industri rev
specialti grow percentag rx spend
back fda grant approv
specialti drug tradit first time
specialti spend grew hep
today report
specialti drug current develop
next-gener blockbust drug primarili
specialti product smaller patient popul
vs tradit mass-market drug blockbust
specialti pipelin inflat need remain robust off-set loss gener growth
debat big threat prove
could
what buzz
alreadi
amzn strength
done healthcar
weak
least state st loui
amazon alreadi begun
drug japanes websit
creat buy partner
 goodrx blink
contract directli
manufactur
amazon own domain
exploratori
talk generic-drug maker
includ sandoz
wholefood purchas
within store
amazon tackl
pharmaci space
purchas stake
drugstor com on-line drug-
store busi back
busi shut year later
amazon could help drug
price transpar issu
compet level play field
exist supplier
lack face-to-fac interact
could big problem key
compon patient engag
pharmaceut industri one
highli regul
industri like amazon
face major oper
creat buy partner
pbm esrx
file state
sell medic devic
suppli equip
deliv non-rx drug
good bartel drug
amazon histori fail
penetr market high barrier
entri amazon prime wine
creat buy partner
pharmaci
premera cross
build intern pbm
capabl employe
pharmaci chain oper
cocokara fine inc
matsumotokyoshi hold
deliv cosmet
drug space alreadi highli
effici distributor take
market
effici suppli chain regulatori hurdl plethora prof servic minim threat
debat vertic integr danc continu
contd vertic integr transform space
achiev industri consum
back bought caremark largest
us pbm transform merger equal
open landscap synergist opportun
acquir catamaran becom
integr value-add synergi includ
enhanc capabl qualiti care expand
geographi diversifi custom base etc
recent two lead player healthcar
aet announc intent join forc
vertic integr
cvs-caremark set chessboard
recent news merger two
healthcar giant esrx could face
differ competit landscap place
expect compani aim becom one-
stop shop healthcar servic innov
grab share especi new potenti player like
amazon continu eye complex
would also help protect polit threat
provid greater transpar price reduc
player negoti power creat effici
purchas includ visibl oop cost
offer better clinic outcom util combo
medic pharmaci claim data
creat formid competitor power
catalyz consolid custom
supplier help enhanc competit
ultim reduc cost burden consum
would also like result firm
pace vertic integr like pick healthcar tend reactionari natur
base rx industri grow msd compound-annual-growth-rate
msd pharma growth sustain
us continu see highest drug inflat
pharmaceut industri forecast grow
compound-annual-growth-rate hsd growth
level seen
new medicin hep-c cancer
contribut strongli year
number factor includ market-access
pressur greater impact patent expiri
continu gener drug deflat contribut
sustain level industri
oncolog autoimmun diabet treatment
drive much growth go forward
us gross/net drug spend reach bn bn
gap gross net drug price
reflect use rebat discount
largest driver growth
drug inflat pictur point stabil mute level
buy-sid gener deflat trend ldd throughout sell-sid trend lower low-mdd
number hyperinfl buy side
number hyperinfl sell side
buy-sid brand inflat track mid hsd histor low-mdd
number hyperinfl
valuat trend lower allow potenti mean revers
rx suppli chain remain one group hc long-term averag despit tax reform upsid
risk point favor risk/reward profil threat dis-infl vs tax reform gm stabil
potenti continu disinfl deflat pressur hit industri profit reset oper margin lower long term
threat govern intervent broadli across complex given consum furor drug price could harm visibl multipl
entranc materi fashion contempl could disrupt busi model compress profit share
stabil gener deflat post period disrupt given format larg buy group could aid return posit omx
improv util due spike flu season gener uptrend given acceler econom condit would aid profit growth
push toward vertic integr provid lt visibl industri econom given abil effect save consum system
bull bear debat thesi
bull bear debat skew favor post difficult
volum recov
sentiment remain
deflat structur
ep continu de-rat
thesi
favor share return thesi hd smith
increment clariti path ep prefer prior
capit notabl depress valuat
share recov notabl post loss tax reform
lessen downsid risk lt question remain
favor share less bad thesi w/ growth like
acceler arbitrag
market assign high probabl success turnaround
given myriad headwind multipl risk
forese investor return given
yield likeli fear abat
initi outperform pt
im one w/
last page report import disclosur regard stock report
tabl content
debat inflationari environ new normal
debat management focu return capit vs growth
financi model path growth re-norm
point differenti vs st
iv valuat risk inflat pictur stabil
 conclus initi outperform prevail
bet big share gain growth diversif
abc stock peak gener inflat boom
newli expand anim health via mwi
thesi stabil macro driver drug complex
yield superior growth given specialti hd smith
vet busi play investor
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk resumpt hyper-deflationari
environ coupl independ price
esrx make almost half abc revenu
stabl manag team transform busi
ex esrx
elect chairman
join compani svp
previous vice-president corpor control sinc
join compani
prior serv vice-president financ syncor
previous serv evp global sourc
manufactur relat
founder lash group
debat inflationari environ new normal
expect jan brand inflat in-lin monitor close
work market growth suggest revenu
suppli chain expand lsd-msd
rate inflat sensit factor notabl
enter inflat level earli jan serv
crucial point data better understand
pharma behavior
last januari came somewhat modest relief
vs investor worri hsd brand
inflat msd gener deflat
close watch commentari
price increas track understand one
mani variabl influenc firm suppli chain
o/p convers return histor level
interest look group op/gp
convers depict spike
relat hyperinfl
gener specialti
op/gp pick tradit
gener deflat stabil depress level
number hyperinfl buy side
number hyperinfl sell side
forese inflat trajectori stabil lesser level translat favor profit outlook
invest redefin custom experi
go forward capital-expenditure normal lower level
commit reorgan
strateg invest revamp dc
shift autom help yield organiz
benefit effici time addit
prepar onboard volum
front compani activ
invest build new robust technolog
platform better support lash group patient servic
also order customer-ord entri fusion
patient support system logist system
abc autom network includ five
seven new dc expect bring last two
on-line end year total dc
opex trend relat manag new dc
howev ramp depress averag om
underli op leverag improv mix also depress impact report om
debat management focu return capit vs growth
acquisit hd smith
purchas bn
purchas bn
hsd ldd revenu
growth help off-set
pharma
expect slow
msd due
cash roi
expect increas repurchas activ time
novemb announc acquisit
 smith largest independ wholesal
center across
subsidiari triplefin acret
includ transact
paid mm cash
acquisit expect slightli
accret ep
expect revenue growth op incom
pharma ds op growth
deal expect close earli
buy hd smith
hd bring higher-margin independ
pharmaci histor
abc larger scale improv gener
sourc like largest sourc cost synergi
acquisit also fill geograph hole
histor horizont bolt-on solid
return pattern hd smith seem like continu
model summari point differenti vs street
swing factor cadenc drug inflat specialti rx growth potenti benefit tax reform
point
peer given share
om pressur
mix despit better
forecast st
market impli
million except per share data fy end septemb organ gp growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount januari
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
tax rate vs prior reform
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total fine hd smith total valu valu per perpetu growth valu enterpris enterpris valu januari
valuat trend notabl lower inflat relat fear
metric final found stabil albeit histor level w/ room upsid growth normal
risk point favor risk reward profil resumpt materi deflat independ pressur unlik
potenti resumpt independ price war result materi margin degrad signific profit pressur
signific downtick sell-sid gener deflat without similar movement buy side margin result overal compress
increment soft pharmedium growth lessen inflat continu challeng relat revamp qc process
polit threat chang rx price methodolog gross net intens scrutini opioid curtail distribut profit
execut challeng onboard hd smith asset potenti leakag key independ custom transit period
inabl transit specialti contract long term new econom allow fair payment differenti servic
conclus initi outperform pt upsid
favor share return thesi hd smith specialti stabl inflat reacceler
decidedli neg rx suppli chain much avoid share
premis market incorrectli discount degre ep de-rat come
industri macro fundament final show sign stabil number co-
specif factor like influenc growth higher return share construct
highlight fact gener deflat independ price worsen
least month cite util continu tepid gener stabl pace
coupl moder intern invest on-board integr
hd smith continu growth mwi specialti see growth reacceler loom
look oi growth return ep approach double-digit
coupl attract yield offer investor reason risk reward
furthermor see upsid option tax reform us well continu
bia toward capit return leverag remain manag even recent tuck-in deal
would also note realli like recent hd smith deal small
like offer attract return vs recent growth bias
thu see abc current discount attract entri point vs
histor rang contend also fit within macro framework valu revers
given dynam see risk reward favor thu initi share o/p rate
thing watch tone gener drug price omx trajectori revenu growth
initi pt
difficult alway motion futur
last page report import disclosur regard stock report
tabl content
debat like strategi shift given management transit
debat put take impact medic busi
debat relationship offer stabil growth option
point differenti vs st
iv valuat risk price-to-earnings discount vs visibl
 conclus initi await reacceler
divest distribut busi china
thesi result improv
balanc await proof point
medic strategi prior becom construct
rate valuat pt pt
ebitda vs average
price-to-earnings vs average
risk challeng integr patient recoveri
period increas competit deflat
retail busi account revenu
new regim follow much legaci game plan
serv current role sinc
retir januari
held number senior oper sale
financ role year cardin
previous gari mari west wireless health
institut jnj comprehens care group
previous serv presid us pharma
distribut evp pharma oper
debat like strategi shift given transit
georg barrett transform cardin
cardin spent bn medic
expans differ medic devic aim
help reduc cost mani high price item
drive total healthcar spend
current ceo georg barrett join cardin
sinc institut broad array strateg
increas dividend yield
enter china plan divest given
address cah rel weak specialti
continu add heft pharma via tuck-in
invest cardin medic busi
cardin invest gener medic
devic addit scale see next box
mike kaufmann like continu vein
div pay-out may peak shift repo/m
georg barrett recent announc retir
effect januari replac mike
georg step chairman nov
jorg gomez current cfo medic becom cfo
mike jorg cardin veteran year
given signific involv realiz
current strategi new team unlik institut
major strateg pivot short-to-medium term
dont expect make dramat chang
weve built mike ep call
gross debt ebitda
new manag unlik herald new era w/ bia dividend vs repurchas key
yearassetproduct areasacq lt cardiolog recoverymdt patient care dvt nutrit bn januari
debat put take impact medic
pois disrupt medic suppli industri
omi/medlin select aggress price
amazon march transform virtual everi
segment economi compani seem
activ eye segment could larg scale
medic suppli distribut next
amazon busi alreadi featur array basic
medic suppli infus pump cathet iv bag
sutur etc price lower competitor
due regulatori hurdl though question
whether could sell higher-end product
implant cardiolog orthoped devic drug
requir licens commod item particularli
non-hospit set would notabl easier
recent acquisit perform mix
cah medic busi face varieti hw
cordiss perform sinc acquisit stellar
earli va announc
synergi taken longer ramp expect
cah lack histor presenc outsid us
build manufactur back offic
howev recent commerci momentum
fx hw last quarter
caus mm hw
patient recoveri newli close perform
expect also benefit cordi invest
select provid medic product reduc
size cah prior contract bn
full effect began impact
inventori step compress initi accret
cardin face suppli challeng glove relat
old manufactur contract result mm
payment regain direct distribut certain market
one time repeat futur
medic remain key swing factor share w/ nt headwind vs lt opportun
debat relationship offer stability/growth option
red oak prove strateg modest ep accret
cvss win optumrx increas scale
found decemb run
follow summer red oak largest us-focus
drug buy entiti bn gener purchas
headquart foxborough jv jointli
staf fund
base size dispar
agre pay mm
rais mm eight year red oak
hit perform target
estim red oak therefor provid steadi
hsd percent ep accret per year provid
major earn tailwind although increment less
given benefit look expans opportun
would red oak expans over-the-counter look like
red oak expans specialti drug
given success red oak gener drug one
potenti sourc increment earn growth could
come expans adjac area over-
over-the-counter product current repres bn
revenu bn
could see sourc save
specialti drug could anoth area save red
given negoti dynam specialti drug
estim save potenti
potenti ep accret specialti drug
potenti ep accret over-the-counter product
model summari point differenti vs street
swing factor pharma omx cadenc medic om growth patient recoveri
point
st given
conserv view
primarili mix drive
st
given
risk await visibl
million except per share data fy end june organ gp growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount januari
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
tax rate vs prior reform
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
metric increment intrigu given under-perform seek clariti path
risk point balanc risk reward profil execut medic integr crucial given challeng
potenti resumpt independ price war result materi margin degrad signific profit pressur
signific downtick sell-sid gener deflat without similar movement buy side margin result overal compress
challeng integr patient recoveri asset period mix overal medic perform sluggish util
om firm improv base medic busi invest period subsid synergi ramp becom increasingli appar
recent combin creat new vertic partnership expans enhanc alreadi success exist relationship
recent pass tax reform free capit quickli de-lever post patient recoveri return capit sharehold
conclus initi pt upsid
increment clariti path ep prefer prior capit notabl depress valuat
decidedli neg rx suppli chain much howev complet
mis-tim upgrad share prior materi de-rat year ep estim
increasingli confid result improv balanc year
macro headwind drug price abat cite less visibl desir ep path
much uncertainti come trajectori medic busi undergon
massiv transform current midst integr sizeabl deal
remain confid strategi pursu howev cite time need
execut turnaround patient recoveri busi declin upon time deal
furthermor util broadli challeng sign improv
invest also still put segment order firm ex us sale channel
base factor recent sale china busi see downsid risk
forecast certainli initi first blush contend may take longer recoveri evid
said sentiment appear terribl share valuat near decad low
hefti dividend yield present support stock current limit downsid risk
all-in see mean revers argument prefer see anoth result
would like primari work medic prior becom construct
given dynam see risk reward balanc thu initi share rate
thing watch tone gener price medic omx trajectori commentari
initi pt
independ tri
last page report import disclosur regard stock report
tabl content
debat esrx stay independ
debat right long-term margin profil post
debat expect see deal like evicor
financi model prepar
point differenti vs st
iv valuat risk tax reform vs margin path
strategi focus enhanc pbm capabl
recent lost largest client
certainti tax reform improv share
potenti lt margin/strategi question linger
rate valuat pt pt
risk pbm margin dip vertic
profit mix remain skew mail specialti
cfo role volatil commun improv
join compani medco merger
previous serv ceo accredo
join esrx svp cfo
previous own havel associ
independ consult firm serv
cfo major brand hold
recent serv svp oper
debat esrx stay independ
mco outsourc pbm servic save time in-sourc high-valu function
aet outsourc
esrx
insourc
mh
larg mco
acquisit aet
ci remain
mco re-in-h pbm servic
commentari gener manufactur
esrx independ notabl except
two main reason
payer keep valu chain
benefit pbm scale
low-valu ad servic
data data data
tighter integr pharmaci
medic claim data provid
complet patient pictur lower
overal cost care
vertic integr increas across pharma
suppli chain pbm also sought join forc
pharmaci increas data pool cost manag
despit tighter integr mani particip
health care servic broadli express script
persist assert desir maintain
time per ep call esrx mention
independ model
howev esrx run risk becom wallflow
hc servic compani pair provid
integr offer esrx limit data
question esrx stay independ
pbm often creat opportun competitor
esrx take advantag current market disrupt
pbm creat servic disrupt merg
compani often focus integr plan and/or
client perceiv conflict interest new
loss bn retent rate
rate
bcb rhode island regencerx
esrx right ship smooth sail guarante
express script spent lot effort past
year overcom perceiv shortcom
improv servic level overcut staff
revamp websit mail order improv
patient friendli eas use
esrx also continu roll innov program
inflat cap popular though arguabl limit
good safeguardrx expans new diseas
state ms opioid addict
express script need confront rel pauciti
data find new way improv cost outcom
larg number health plan client current
includ medicar part
key concern health plan client feel
work joint pbm issu
unh/ctrx
addit expect esrx aggress
market current capabl improv servic level
competit price captur addit share
given histor exampl uncommon client
retent level fall least short term
assum retent rate
sell season competitor could hit
esrx could like win
contract given size capabl
given first-year oper margin lower
corpor averag given start-up cost
estim win could gener
ep esrx
independ may prove posit near-term long-term question still remain
retent market share biz year contract januari
debat right lt margin profil post
esrx margin vari wide product offer
major differ also exist product type
esrx handl transit w/ care
esrx middl hc servic
see esrx emerg w/ core margin lt upper-end peer given mix
om risk losspotenti margin offsetsmodest fix cost bn revenu bn mm restructur program institut save attrit could increas other follow door esrx may abl win share largest competitor smaller scale could neg impact gener purchas rebatesesrx join wbad leverag buy group superior pricingpharmaci chain may push back favor reimburs rate given lower rxsremain seen esrx still one largest pbm januari
debat expect see deal like evicor
evicor confus evercor
asset might esrx look
evicor medic benefit manag compani
lab would add addit patient data
aim reduc cost improv outcom
help payer develop clinical-bas guidelin
treatment nine area
acquisit help expand number area
express script help client manag cost
almost doubl tam
one largest obviou tuck-in remain
help esrx move medic remain
independ manag care
financi detail purchas price bn
acquisit would bring materi up-tick capit
intens touch small hc cost
pbm addit tuck-in possibl sizeabl asset
unlik gain regulatori approv
would provid addit patient data
could marri rx data improv esrx offer
medic manag
manag would provid richest sourc patient
data integr cost manag esrx would
give cherish independ model acquir
sizeabl asset might financi tax
esrx like remain repo bias w/ small tuck-in
went repo share could fall
expect increas bia toward debt pay-down mix repurchas tuck-in
model summari point differenti vs street
swing factor plan market share price pressur vertic integr de-lever
point
expect up-tick
prior hit
restructur ramp
ep street elev
leverag manag
expect increas bia toward debt pay-down mix repurchas tuck-in
million except per share data fy end decemb growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount januari
dcf summari dcf deriv pt impli termin growth rate
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per esrx perpetu growth valu enterpris enterpris valu januari
valuat posit bias reform anthem certainti
valuat pressur given overhang busi model question polit uncertainti
risk point balanc risk reward profil polit uncertainti remain toughest quantifi
potenti elev govern scrutini drug price transpar neg impact long-term profit gener via
share loss newli form vertic integr healthcar servic model given cost outcom inferior disadvantag
continu stagnat high profit margin mail pharmaci unit long-term potenti threat on-line competit
potenti share gain via market disrupt newli form entiti given concern competit exist health plan
tax reform provid materi ep upsid gain compet away allow appeal drop-through
pursuit vertic integr creat strateg option despit cliff ep ebitda
conclus initi pt upsid
share recov notabl post loss tax reform lessen downsid risk lt question remain
quit neg share esrx much last year base view
elev risk surround potenti contract loss size headwind
also highlight potenti polit risk given increas focu drug price
pbm gross-to-net bubbl epicent contenti debat
enter increas visibl outcom potenti
ebitda hit although polit landscap remain somewhat uncertain
new specter hang suppli chain although would character
threat less worrisom ultim mind overdon
thu key risk abat new upsid driver emerg notabl tax
reform still reserv respect long-term busi model
concern base potenti threat integr healthcar servic model
may prove structur advantag cost outcom
main concern see entiti potenti price pressur larg
diversifi provid may will accept lower margin go forward order drive share
across full enterpris pbm suscept view given low capit requir
given dynam recent ralli share nearli move sinc mid-oct see
risk reward balanc current thu initi share rate
thing watch share tone vertic integr om trajectori
initi outperform pt
would honor would join us o/p
last page report import disclosur regard stock report
